No abstract available. Billig HE Jr, Morehouse LE. Performance and metabolic alterations during betaine glycocyamine feeding in myasthenia gravis. Arch Phys Med Rehabil. 1955;36(4):233-236.
Read MoreNo abstract available. Basom WC, Breck LW, Leonard MH. The effect of betaine and glycocyamine in the management of chronic anterior poliomyelitis. Int Rec Med Gen Pract Clin. 1955;168(2):70-71.
Read MoreNo abstract available. Watkins AL. Betaine and glycocyamine in the treatment of poliomyelitis. N Engl J Med. 1953;248(15):621-623. doi:10.1056/NEJM195304092481501
Read MoreNo abstract available. Fallis BD, Lam RL. Betaine and glycocyamine therapy for the chronic residuals of poliomyelitis. J Am Med Assoc. 1952;150(9):851-853. doi: 10.1001/jama.1952.03680090015007
Read MoreNo abstract available. Borsook ME, Billig HK, Golseth JG. Betaine and glycocyamine in the treatment of disability resulting from acute anterior poliomyelitis. Ann West Med Surg. 1952;6(7):423-427.
Read More
Twenty-two patients with arthritis received 5 gm of glycocyamine and 20.16 gm of betaine by mouth daily, in hospital and after discharge, for periods ranging from 13 to 42 days. A control group of 22 patients, indistinguishable from the treated group, were maintained on the same regimen and given placebos resembling the agents under study. […]
Read MoreNo abstract available. Graybiel A, Patterson CA. Use of betaine and glycocyamine in the treatment of patients with heart disease: preliminary report. Ann West Med Surg. 1951;5(10):863-875.
Read MoreNo abstract available. Borsook ME, Borsook H. Treatment of cardiac decompensation with betaine and glycocyamine. Ann West Med Surg. 1951;5(10):830-855.
Read MoreNo abstract available. Borsook H, Borsook ME. The biochemical basis of betaine-glycocyamine therapy. Ann West Med Surg. 1951;5(10):825-829.
Read More